Role of maspin in cancer

Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily. Its expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic, gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activities in different cell types. However, maspin expression seems to be correlated with better prognosis in prostate, bladder, lung, gastric, colorectal, head and neck, thyroid and melanoma cancer. In breast and ovarian cancer maspin significance is associated with its subcellular localization: nucleus maspin expression correlates with a good prognosis, whilst in pancreatic cancer it predicts a poor prognosis. Since tumor metastasis requires the detachment and invasion of tumor cells through the basement membrane and stroma, a selectively increased adhesion by the presence of maspin may contribute to the inhibition of tumor metastasis. Furthermore the different position of maspin inside the cell or its epigenetic modifications may explain the different behavior of the expression of maspin between tumors. The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age, comorbidities, blood examinations in order to select the best therapy to be carried out. Focusing on the malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the expression of maspin, to identify natural substances that can determine the activation and the expression of maspin or possible “molecules binds” to introduce maspin in cancer cell and gene therapy capable of up-regulating the maspin in an attempt to reduce primarily the risk of metastasis.Further studies in these directions are necessary to better define the therapeutic implication of maspin.

[1]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[2]  K. Tsuneyama,et al.  Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. , 2007, Anticancer research.

[3]  A. Hartmann,et al.  Nuclear Maspin expression is associated with response to adjuvant 5‐fluorouracil based chemotherapy in patients with stage III colon cancer , 2006, International journal of cancer.

[4]  L. Giacomelli,et al.  MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma , 2008, European Archives of Oto-Rhino-Laryngology.

[5]  P. Surowiak,et al.  Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma. , 2010, Folia morphologica.

[6]  Y. Yatabe,et al.  Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation , 2004, Oncogene.

[7]  H. Mehdorn,et al.  Expression of metastasis suppressor gene maspin is reduced in breast cancer brain metastases and correlates with the estrogen receptor status , 2010, Neurological research.

[8]  F. Kittrell,et al.  Modeling human breast cancer metastasis in mice: maspin as a paradigm. , 2003, Histology and histopathology.

[9]  S. Sheng,et al.  Bax Mediates the Apoptosis-Sensitizing Effect of Maspin , 2004, Cancer Research.

[10]  Ming Zhang,et al.  Maspin Mediates Increased Tumor Cell Apoptosis upon Induction of the Mitochondrial Permeability Transition , 2005, Molecular and Cellular Biology.

[11]  Z. Szentirmay,et al.  Possible predictive value of maspin expression in colorectal cancer. , 2013, Recent patents on anti-cancer drug discovery.

[12]  Jeffrey W. Smith,et al.  Maspin alters the carcinoma proteome , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  J. López-Guerrero,et al.  Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukapheresis products from patients with breast cancer: comparison with immunocytochemistry. , 1999, Journal of hematotherapy.

[14]  M. Hendrix,et al.  Maspin: molecular mechanisms and therapeutic implications , 2012, Cancer and Metastasis Reviews.

[15]  S. Sheng.  Maspin: A Novel Serine Protease Inhibitor , 2005 .

[16]  S. Sheng,et al.  Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. , 2006, Cancer research.

[17]  Nehad M R Abd El-Maqsoud,et al.  Loss of Maspin Expression in Bladder Cancer: Its Relationship with p53 and Clinicopathological Parameters. , 2010, Journal of the Egyptian National Cancer Institute.

[18]  Ming Zhang,et al.  Targeting maspin in endothelial cells to induce cell apoptosis , 2006, Expert opinion on therapeutic targets.

[19]  T. Nakashima,et al.  Maspin expression in stage I and II oral tongue squamous cell carcinoma , 2001, Head & neck.

[20]  A. Miyauchi,et al.  Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. , 2004, Thyroid : official journal of the American Thyroid Association.

[21]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[22]  M. Fukushima,et al.  Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. , 2005, The Annals of thoracic surgery.

[23]  H. Mukhtar,et al.  Antiproliferative Effects of Apple Peel Extract Against Cancer Cells , 2010, Nutrition and cancer.

[24]  J. Aguirre-Ghiso,et al.  Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. , 2000, Current opinion in cell biology.

[25]  F. Kayaselçuk,et al.  Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. , 2008, Pathology, research and practice.

[26]  Yan Li,et al.  Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. , 2004, World journal of gastroenterology.

[27]  M. Hendrix,et al.  Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells , 2005, Cancer biology & therapy.

[28]  Y. Sagara,et al.  Expression of maspin predicts poor prognosis in breast‐cancer patients , 2002, International journal of cancer.

[29]  N. Kapucuoglu,et al.  Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters , 2010, Pathology & Oncology Research.

[30]  J. Arbiser,et al.  Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. , 2009, Journal of the American Academy of Dermatology.

[31]  M. Hendrix,et al.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.

[32]  P. Furth,et al.  Maspin plays an important role in mammary gland development. , 1999, Developmental biology.

[33]  H. Lehnert,et al.  [Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis]. , 2004, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[34]  John R Yates,et al.  Maspin and tumor metastasis , 2006, IUBMB life.

[35]  S. Sheng,et al.  Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF‐A levels and in Stage I, improved survival , 2009, Histopathology.

[36]  J. Burke,et al.  Sufficiency of the Reactive Site Loop of Maspin for Induction of Cell-Matrix Adhesion and Inhibition of Cell Invasion , 2003, Journal of Biological Chemistry.

[37]  H. Biliran,et al.  Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. , 2001, Cancer research.

[38]  A. Maitra,et al.  Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation , 2005, International journal of gastrointestinal cancer.

[39]  W. Jonat,et al.  Expression and regulation of tumor suppressor gene maspin in human bladder cancer. , 2004, Cancer letters.

[40]  N. Kyprianou,et al.  Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT , 2008, Oncogene.

[41]  R. Schneider-Stock,et al.  Maspin in thyroid cancer: its relationship with p53 and clinical outcome. , 2003, Oncology reports.

[42]  Ming Zhang,et al.  Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. , 2002, International journal of oncology.

[43]  Z. Culig,et al.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.

[44]  M. Hendrix,et al.  Editor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma , 2002, Clinical Cancer Research.

[45]  Hanlin L. Wang,et al.  Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. , 2012, Archives of pathology & laboratory medicine.

[46]  J. Rosen,et al.  Maspin Is Physically Associated with ␤1 Integrin Regulating Cell Adhesion in Mammary Epithelial Cells , 2022 .

[47]  S. Gasparini,et al.  Maspin expression is a favorable prognostic factor in non-small cell lung cancer. , 2012, Analytical and quantitative cytology and histology.

[48]  H. Yoshida,et al.  Expression of maspin is up‐regulated during the progression of mammary ductal carcinoma , 2003, Histopathology.

[49]  R. Samaka,et al.  Maspin protein expression: a special feature of papillary thyroid carcinoma. , 2006, Journal of the Egyptian National Cancer Institute.

[50]  S. Mirza,et al.  Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression , 2011, Tumor Biology.

[51]  D. Jonas,et al.  New molecular mediators in tumor angiogenesis , 2000, Journal of cellular and molecular medicine.

[52]  L. Giacomelli,et al.  Nuclear MASPIN expression relates to a better prognosis in elderly patients with laryngeal carcinoma , 2011, Acta oto-laryngologica.

[53]  C. Pedone,et al.  Peptide‐based Molecules in Angiogenesis , 2006, Chemical biology & drug design.

[54]  O. Blacque,et al.  Evidence for a Direct Interaction between the Tumor Suppressor Serpin, Maspin, and Types I and III Collagen* , 2002, The Journal of Biological Chemistry.

[55]  A. Hartmann,et al.  Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer , 2005, The Journal of pathology.

[56]  S. Choi,et al.  Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer , 2010, Tumor Biology.

[57]  Mi-ja Lee,et al.  Clinicopathological Significance of Maspin Expression in Breast Cancer , 2006, Journal of Korean medical science.

[58]  E. Yamamoto,et al.  Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[59]  A. Tanimoto,et al.  Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer , 2011, Diagnostic pathology.

[60]  J. R. Erickson,et al.  Maspin Is an Intracellular Serpin That Partitions into Secretory Vesicles and Is Present at the Cell Surface , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[61]  A. Nm,et al.  Loss of Maspin Expression in Bladder Cancer: Its Relationship with p53 and Clinicopathological Parameters. , 2010 .

[62]  P. Lizardi,et al.  Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor , 2008, Molecular Cancer Therapeutics.

[63]  S. Sheng,et al.  Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[64]  W. Jonat,et al.  Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer. , 2010, Anticancer research.

[65]  Wei Zhang,et al.  Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  D. Wingate.  Epithelia , 1989 .

[67]  S. Sheng,et al.  Tumor suppressive maspin and epithelial homeostasis , 2006, Journal of cellular biochemistry.

[68]  E. Yamamoto,et al.  Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. , 2011, Oncology reports.

[69]  M. A. El-Wahed.  Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. , 2005 .

[70]  J. Emerich,et al.  Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. , 2009, Gynecologic oncology.

[71]  R. Ball,et al.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues , 2005, British Journal of Cancer.

[72]  T. Iwaya,et al.  Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis , 2006, Journal of Clinical Pathology.

[73]  M. Federico,et al.  Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  F. Fazi,et al.  Dynamic and reversibility of heterochromatic gene silencing in human disease , 2005, Cell Research.

[75]  R. Ralhan,et al.  Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. , 2009, Chemico-biological interactions.

[76]  R. Momparler,et al.  Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines , 2004, Anti-cancer drugs.

[77]  S. Sheng.  A role of novel serpin maspin in tumor progression: The divergence revealed through efforts to converge , 2006, Journal of cellular physiology.

[78]  Ming Zhang,et al.  Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins , 2005, BMC Cancer.

[79]  A. Bosserhoff,et al.  Loss of maspin expression contributes to a more invasive potential in malignant melanoma. , 2007, Pigment cell research.

[80]  M. Hendrix,et al.  maspin suppresses the invasive phenotype of human breast carcinoma. , 1998, Cancer research.

[81]  L. Frémont.  Biological effects of resveratrol. , 2000, Life sciences.

[82]  J. Whisstock,et al.  The High Resolution Crystal Structure of the Human Tumor Suppressor Maspin Reveals a Novel Conformational Switch in the G-helix* , 2005, Journal of Biological Chemistry.

[83]  K. Yamaguchi,et al.  Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. , 2001, Cancer letters.

[84]  A. Berchuck,et al.  Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[85]  J. Serth,et al.  Expression of the p53 and maspin protein in primary prostate cancer: Correlation with clinical features , 2001, International journal of cancer.

[86]  M. J. Requena Tapia,et al.  [The 2004 WHO classification of bladder tumors: a summary and commentary]. , 2007, Actas urologicas espanolas.

[87]  D. Grignon,et al.  Maspin is up‐regulated in premalignant prostate epithelia , 2002, The Prostate.

[88]  Moshira Abd El-Wahed.  Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. , 2005, Journal of the Egyptian National Cancer Institute.

[89]  T. Abiko,et al.  Expression of maspin in non-small-cell lung cancer: correlation with clinical features. , 2008, Clinical lung cancer.

[90]  T. Athanasiou,et al.  Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer , 2006, Journal of Clinical Pathology.

[91]  P. Heikkilä,et al.  High expression of maspin is associated with early tumor relapse in breast cancer. , 2009, Human pathology.

[92]  W. Jonat,et al.  Expression of the tumor suppressor gene Maspin in human pancreatic cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  Z. Khalkhali‐Ellis.  Maspin: The New Frontier , 2006, Clinical Cancer Research.

[94]  S. Maxwell,et al.  Red wine and antioxidant activity in serum , 1994, The Lancet.

[95]  F. Rösel,et al.  Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast , 2001, The Journal of pathology.

[96]  A. Viale,et al.  Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction , 2001, Bone Marrow Transplantation.

[97]  B. Cuevas,et al.  Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors , 2007, Oncogene.

[98]  L. Coussens,et al.  IKKα at the Crossroads of Inflammation and Metastasis , 2007, Cell.

[99]  R. Herrmann,et al.  Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. , 2010, Human pathology.

[100]  F. Carinci,et al.  Maspin Expression in Oral Squamous Cell Carcinoma , 2007, The Journal of craniofacial surgery.

[101]  Hong Duan,et al.  Role for DNA methylation in the control of cell type–specific maspin expression , 2002, Nature Genetics.

[102]  Chaehwa Park,et al.  Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[103]  Phillip Koeffler,et al.  Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation , 2010, BMC Cancer.

[104]  T. Masuda,et al.  Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. , 2004, The Journal of investigative dermatology.

[105]  J. Whisstock,et al.  Maspin (SERPINB5) Is an Obligate Intracellular Serpin* , 2010, The Journal of Biological Chemistry.

[106]  L. Giacomelli,et al.  Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease‐free interval after surgery for squamous cell carcinoma of the larynx , 2005, Histopathology.

[107]  V. Giguère,et al.  Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis , 2011, Laboratory Investigation.

[108]  M. Bar‐eli,et al.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype , 2010, Proceedings of the National Academy of Sciences.

[109]  Minjin Kim,et al.  Maspin genetically and functionally associates with gastric cancer by regulating cell cycle progression. , 2012, Carcinogenesis.

[110]  H. Wada,et al.  Maspin Expression and Its Clinical Significance in Non-Small Cell Lung Cancer , 2006, Annals of Surgical Oncology.

[111]  J. Sohn,et al.  Association of maspin expression with the high histological grade and lymphocyte‐rich stroma in early‐stage breast cancer , 2003, Histopathology.

[112]  V. Odero-Marah,et al.  Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells , 2012, BMC Cancer.

[113]  A. Munkarah,et al.  Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. , 2006, Gynecologic oncology.

[114]  L. Bubendorf,et al.  Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer , 2006, Journal of Clinical Pathology.

[115]  Yu-cai Fu,et al.  Cellular and molecular effects of resveratrol in health and disease , 2012, Journal of cellular biochemistry.

[116]  M. Sonobe,et al.  Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC. , 2006, Lung Cancer.

[117]  Xiu-sheng He,et al.  Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis , 2011, Journal of experimental & clinical cancer research : CR.

[118]  R. Toillon,et al.  Proteomics Demonstration That Normal Breast Epithelial Cells Can Induce Apoptosis of Breast Cancer Cells through Insulin-like Growth Factor-binding Protein-3 and Maspin* , 2007, Molecular & Cellular Proteomics.

[119]  Hyung-Seok Kim,et al.  Maspin and p53 Protein Expression in Gastric Adenocarcinoma and Its Clinical Applications , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[120]  Ming Zhang,et al.  Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis , 2005, Oncogene.

[121]  L. Giacomelli,et al.  Expression of maspin in papillary Ta/T1 bladder neoplasms. , 2008, Anticancer research.

[122]  F. Rösel,et al.  Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. , 2001, Clinical biochemistry.

[123]  S. Sheng,et al.  Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. , 2011, Genes & cancer.

[124]  J. Serth,et al.  Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer. , 2010, Oncology letters.

[125]  R. Sager,et al.  Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[126]  W. Lee,et al.  Expression of Maspin in Colon Cancers: Its Relationship with p53 Expression and Microvessel Density , 2002, Digestive Diseases and Sciences.

[127]  M. Hendrix,et al.  Epigenetic silencing of maspin gene expression in human breast cancers , 2000, International journal of cancer.

[128]  P. Blancafort,et al.  Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs) , 2011, Epigenetics.

[129]  Lei Zhou,et al.  Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry , 2012, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[130]  L. Rybak,et al.  Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway , 2012, PloS one.

[131]  B. Aggarwal,et al.  Curcumin and cancer: an "old-age" disease with an "age-old" solution. , 2008, Cancer letters.

[132]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[133]  D. Jonas,et al.  Clinical relevance of maspin expression in bladder cancer , 2006, World Journal of Urology.

[134]  H. Daida,et al.  Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. , 2005, Human gene therapy.

[135]  R. Sager,et al.  The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.

[136]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[137]  S. Sheng,et al.  Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. , 2006, Lung cancer.

[138]  Shiwu Wu 武世伍,et al.  Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry , 2012, Journal of Huazhong University of Science and Technology [Medical Sciences].

[139]  M. Hendrix,et al.  Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. , 2007, Cancer research.

[140]  Kon-Ho Lee,et al.  Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. , 2008, International journal of molecular medicine.

[141]  M. Bar‐eli,et al.  The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target , 2011, Oncotarget.

[142]  A. Chambers,et al.  An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[143]  J. Ni,et al.  Expressions of maspin, P53 and Skp2 in colorectal tumors and their clinicopathological significance , 2009 .

[144]  R. Siddiqui,et al.  The Beneficial Effects of Nutritional Compounds on Breast Cancer Metastasis , 2011 .

[145]  M. Hendrix,et al.  Maspin Regulates Different Signaling Pathways for Motility and Adhesion in Aggressive Breast Cancer Cells , 2003, Cancer biology & therapy.

[146]  Shijie Sheng,et al.  Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis , 2003, Oncogene.

[147]  G. Martinelli,et al.  Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer , 2004, Clinical Cancer Research.

[148]  F. Domann,et al.  Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression , 2003, Oncogene.

[149]  M. Molloy,et al.  Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node‐positive colonic cancer , 2010, Histopathology.

[150]  H. Yoshida,et al.  Expression of maspin in colorectal cancer. , 2006, In vivo.

[151]  Ricky A. Sharma,et al.  Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. , 2008, Antioxidants & redox signaling.

[152]  L. Giacomelli,et al.  MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence , 2009, Acta oto-laryngologica.

[153]  Z. Gatalica,et al.  Expression of Maspin and Glutathionine-S-Transferase-π in Normal Human Prostate and Prostatic Carcinomas , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[154]  D. Johnston,et al.  High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma , 2000, Oncogene.

[155]  G. Clark,et al.  Maspin expression in invasive breast cancer: association with other prognostic factors , 2003, The Journal of pathology.

[156]  H. Huland,et al.  Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. , 2004, European urology.

[157]  W. Oosterlinck.  Guidelines on diagnosis and treatment of superficial bladder cancer. , 2004, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[158]  V. Ellis,et al.  G-helix of Maspin Mediates Effects on Cell Migration and Adhesion* , 2010, The Journal of Biological Chemistry.

[159]  D. Wong,et al.  The Tumor Suppressor Maspin Does Not Undergo the Stressed to Relaxed Transition or Inhibit Trypsin-like Serine Proteases. , 1995, The Journal of Biological Chemistry.

[160]  V. Ellis,et al.  Maspin Inhibits Cell Migration in the Absence of Protease Inhibitory Activity* , 2002, The Journal of Biological Chemistry.

[161]  E. Çolak,et al.  Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer. , 2012, Tumori.